<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01262638</url>
  </required_header>
  <id_info>
    <org_study_id>ETC-1002-003</org_study_id>
    <nct_id>NCT01262638</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides</brief_title>
  <official_title>A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Esperion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Esperion Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 proof-of-concept study will assess the lipid regulating efficacy and safety of
      ETC-1002 in subjects with hypercholesterolemia and either normal or elevated triglycerides.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the LDL-C lowering efficacy of ETC-1002 versus placebo</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of ETC-1002 to modulate TG and other lipid and cardio-metabolic biomarkers</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess safety using adverse event reports, physical exams, vital signs, ECGs and clinical laboratory parameters</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>ETC-1002 120 mg (Group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with hypercholesterolemia and normal triglycerides</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ETC-1002 80 mg (Group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with hypercholesterolemia and normal triglycerides</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ETC-1002 40 mg (Group 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with hypercholesterolemia and normal triglycerides</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Group 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with hypercholesterolemia and normal triglycerides</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ETC-1002 120 mg (Group 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with hypercholesterolemia and elevated triglycerides</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ETC-1002 80 mg (Group 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with hypercholesterolemia and elevated triglycerides</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ETC-1002 40 mg (Group 7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with hypercholesterolemia and elevated triglycerides</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Group 8)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with hypercholesterolemia and elevated triglycerides</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETC-1002</intervention_name>
    <description>ETC-1002 daily for 12 weeks</description>
    <arm_group_label>ETC-1002 120 mg (Group 1)</arm_group_label>
    <arm_group_label>ETC-1002 80 mg (Group 2)</arm_group_label>
    <arm_group_label>ETC-1002 40 mg (Group 3)</arm_group_label>
    <arm_group_label>ETC-1002 120 mg (Group 5)</arm_group_label>
    <arm_group_label>ETC-1002 80 mg (Group 6)</arm_group_label>
    <arm_group_label>ETC-1002 40 mg (Group 7)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo daily for 12 weeks</description>
    <arm_group_label>Placebo (Group 4)</arm_group_label>
    <arm_group_label>Placebo (Group 8)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          -  Provision of written informed consent prior to any study-specific procedure

          -  Fasting LDL-C between 130 and 220 mg/dL following wash-out of all lipid regulating
             medications and supplements

          -  Fasting triglyceride &lt;400 mg/dL following wash-out of all lipid regulating medications
             and supplements

          -  BMI between 18 and 35 mg/kg2

        Major Exclusion Criteria:

          -  Clinically significant cardiovascular disease, diabetes or uncontrolled hypertension

          -  Females of child bearing potential (i.e., females who are not surgically sterile or
             post-menopausal)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2010</study_first_submitted>
  <study_first_submitted_qc>December 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2010</study_first_posted>
  <disposition_first_submitted>August 13, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>August 27, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 11, 2015</disposition_first_posted>
  <last_update_submitted>August 27, 2015</last_update_submitted>
  <last_update_submitted_qc>August 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

